4-氯甲基-3-氰基吡啶 | 1060802-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氯甲基-3-氰基吡啶
• 英文名称: 4-(chloromethyl)nicotinonitrile
• 英文别名: 4-(chloromethyl)pyridine-3-carbonitrile
• CAS: 1060802-60-9
• 化学式: C₇H₅ClN₂
• 分子量: 152.583
• InChiKey: XMGVMOVUVZVEJU-UHFFFAOYSA-N

物化性质

• 沸点：
  279.0±25.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氯甲基-3-氰基吡啶 、 (R)-2-(2-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)piperazin-1-yl)pyrimidin-5-ol 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 70.0h， 以55%的产率得到4-{[(2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}pyridine-3-carbonitrile
  参考文献：
  名称：

  Therapeutic Agents 812

  摘要：

  公式I的化合物或其药用可接受的盐，制备这类化合物的方法，它们作为GPR119调节剂的用途，它们的治疗用途的方法，特别是在肥胖和糖尿病的治疗中，以及含有它们的药物组合物。

  公开号：

  US20110065706A1
• 作为产物：
  描述：

  3-氰基-4-甲基吡啶 在 磺酰氯 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 3.0h， 以61.6%的产率得到4-氯甲基-3-氰基吡啶
  参考文献：
  名称：

  Therapeutic Agents 812

  摘要：

  公式I的化合物或其药用可接受的盐，制备这类化合物的方法，它们作为GPR119调节剂的用途，它们的治疗用途的方法，特别是在肥胖和糖尿病的治疗中，以及含有它们的药物组合物。

  公开号：

  US20110065706A1

文献信息

• [EN] OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS<br/>[FR] DÉRIVÉS DE PYRIDINE OXYDABLE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTI ALZHEIMER
  申请人：INSA INST NAT DES SCIENCES APPLIQUÉES DE ROUEN

  公开号：WO2014114742A1

  公开（公告）日：2014-07-31

  A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2, Z is CH or N or Z is C and - CHR3- is =CH- linked by the double bond to cyclopentanone; or - (-)m- is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N heteroaryl; R8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR', CN, COR, CF3, SOR, SO2R, SONRR', SO2NRR', NO2, halogen, heteroaryl; and the pharmaceutical salts and stereisomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer's disease.

  式（I）的化合物，其中虚线表示至少存在一条双键；n = 0至4；R3和R4为H，或当n = 1时，R3和R4也可以共同形成碳原子之间的双键，m = 0、1或2，Z为CH或N，或Z为C且-CHR3-为=CH-通过双键连接到环戊酮；或-（-）m-不存在，Z为NH，>N-烷基，>N-苯基，>N-苄基或> N杂环烷基；R8为烷基、芳基或杂环烷基，可以选择性地被取代；EWG代表从包括COOR、COSR、CONRR'、CN、COR、CF3、SOR、SO2R、SONRR'、SO2NRR'、NO2、卤素、杂环烷基在内的电子吸引基团；以及其药用盐和立体异构体。式（I）的化合物在治疗诸如阿尔茨海默病等神经退行性疾病方面具有很强的作用。
• Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents
  申请人：INSA (Institut National des Sciences Appliquees) de Rouen

  公开号：EP2759536A1

  公开（公告）日：2014-07-30

  A compound of the formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2, Z is CH or N or Z is C and -CHR3- is =CH- linked by the double bond to the cyclopentanone; or -(-)m- is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N-heteroaryl; R8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR', CN, COR, CF3, SOR, SO2R, SONRR', SO2NRR', NO2, halogen, heteroaryl; and the pharmaceutical salts or tautomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer's disease.

  式(I)的化合物，其中虚线表示至少存在一个双键；n = 0到4；R3和R4为H，或当n = 1时，R3和R4也可以一起形成碳原子之间的双键，m = 0、1或2，Z为CH或N，或Z为C且-CHR3-为=CH-，通过双键与环戊酮相连；或-(-)m-不存在，Z为NH，>N-烷基，>N-苯基，>N-苄基或>N-杂环烷基；R8为烷基、芳基或杂环烷基，可选择性地取代；EWG代表从COOR、COSR、CONRR'、CN、COR、CF3、SOR、SO2R、SONRR'、SO2NRR'、NO2、卤素、杂环烷基组成的电子吸引基团；以及其药用盐或互变异构体。式(I)的化合物在治疗像阿尔茨海默病这样的神经退行性疾病中具有很强的作用。
• OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS
  申请人：INSA (INSTITUT NATIONAL DES SCIENNCES APPLIQUÉES) DE ROUEN

  公开号：US20150353493A1

  公开（公告）日：2015-12-10

  A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n=0 to 4; R 3 and R 4 are H, or when n=1, R 3 and R 4 can also form together a double bond between the carbon atoms, and m=0, 1 or 2, Z is CH or N or Z is C and —CHR 3 — is ═CH— linked by the double bond to cyclopentanone; or −(−) m - is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N heteroaryl; R 8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR′, CN, COR, CF 3 , SOR, SO 2 R, SONRR′, SO 2 NRR′, NO 2 , halogen, heteroaryl; and the pharmaceutical salts and stereisomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer's disease.

  式(I)的化合物中，虚线表示存在至少一个双键；n = 0至4；R3和R4为H，或当n = 1时，R3和R4也可以共同形成碳原子之间的双键，m = 0、1或2，Z为CH或N，或者Z为C，-CHR3-与环戊酮通过双键连接，或-(-)m-不存在，Z为NH，>N-烷基，>N-苯基，>N-苯甲基或> N杂环芳基；R8为烷基、芳基或杂环芳基，可以选择性地被取代；EWG代表从COOR、COSR、CONRR'、CN、COR、CF3、SOR、SO2R、SONRR'、SO2NRR'、NO2、卤素、杂环芳基中选择的电子吸引基；以及其药物盐和立体异构体。式(I)的化合物在治疗神经退行性疾病，如阿尔茨海默病方面具有很强的疗效。
• Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation
  作者：James S. Scott、Alan M. Birch、Katy J. Brocklehurst、Anders Broo、Hayley S. Brown、Roger J. Butlin、David S. Clarke、Öjvind Davidsson、Anne Ertan、Kristin Goldberg、Sam D. Groombridge、Julian A. Hudson、David Laber、Andrew G. Leach、Philip A. MacFaul、Darren McKerrecher、Adrian Pickup、Paul Schofield、Per H. Svensson、Pernilla Sörme、Joanne Teague

  DOI：10.1021/jm300310c

  日期：2012.6.14

  G protein coupled receptor 119 (GPR119) is viewed as an attractive target for the treatment of type 2 diabetes and other elements of the metabolic syndrome. During a program toward discovering agonists of GPR119, we herein describe optimization of an initial lead compound, 2, into a development candidate, 42. A key challenge in this program of work was the insolubility of the lead compound. Small-molecule crystallography was utilized to understand the intermolecular interactions in the solid state and resulted in a switch from an aryl sulphone to a 3-cyanopyridyl motif. The compound was shown to be effective in wild-type but not knockout animals, confirming that the biological effects were due to GPR119 agonism.
• CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS
  申请人：Novartis AG

  公开号：EP1966215A1

  公开（公告）日：2008-09-10